awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q42412173-FAD2E6C3-9066-4917-89C1-C9E7D6B3E664
Q42412173-FAD2E6C3-9066-4917-89C1-C9E7D6B3E664
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42412173-FAD2E6C3-9066-4917-89C1-C9E7D6B3E664
Lessons from the withdrawal of rofecoxib.
P2860
Q42412173-FAD2E6C3-9066-4917-89C1-C9E7D6B3E664
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42412173-FAD2E6C3-9066-4917-89C1-C9E7D6B3E664
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6b2a74f8ec7b4feeb521b75dafd003e1e60d5c17
P2860
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?